232 related articles for article (PubMed ID: 31600981)
1. Intersectoral Cost of Treating Pulmonary Non-Tuberculosis Mycobacterial Disease (NTM-PD) in Germany-A Change of Perspective in Disease Management.
Diel R; Mertsch P
Int J Environ Res Public Health; 2019 Oct; 16(20):. PubMed ID: 31600981
[TBL] [Abstract][Full Text] [Related]
2. The cost of Mycobacterium avium complex lung disease in Canada, France, Germany, and the United Kingdom: a nationally representative observational study.
Goring SM; Wilson JB; Risebrough NR; Gallagher J; Carroll S; Heap KJ; Obradovic M; Loebinger MR; Diel R
BMC Health Serv Res; 2018 Sep; 18(1):700. PubMed ID: 30200944
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and treatment outcomes of pleural effusions in patients with nontuberculous mycobacterial disease.
Park S; Jo KW; Lee SD; Kim WS; Shim TS
Respir Med; 2017 Dec; 133():36-41. PubMed ID: 29173447
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic Maintenance and Redevelopment of Nontuberculous Mycobacteria Pulmonary Disease after Treatment of Mycobacterium avium Complex Pulmonary Disease.
Zo S; Kim H; Kwon OJ; Jhun BW
Microbiol Spectr; 2022 Aug; 10(4):e0108822. PubMed ID: 35950873
[TBL] [Abstract][Full Text] [Related]
5. Mycobacterium avium complex pulmonary disease: management options in HIV-negative patients.
Ramirez J; Mason C; Ali J; Lopez FA
J La State Med Soc; 2008; 160(5):248-54; quiz 254, 293. PubMed ID: 19048978
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors for a one-year improvement in nontuberculous mycobacterial pulmonary disease: An 11-year retrospective and multicenter study.
Cadelis G; Ducrot R; Bourdin A; Rastogi N
PLoS Negl Trop Dis; 2017 Aug; 11(8):e0005841. PubMed ID: 28787454
[TBL] [Abstract][Full Text] [Related]
7. [Strategies for Mycobacterium avium complex infection control in Japan: how do they improve the present situation?].
Ogawa K; Sano C
Kekkaku; 2013 Mar; 88(3):355-71. PubMed ID: 23672176
[TBL] [Abstract][Full Text] [Related]
8. A Laboratory-based Analysis of Nontuberculous Mycobacterial Lung Disease in Japan from 2012 to 2013.
Morimoto K; Hasegawa N; Izumi K; Namkoong H; Uchimura K; Yoshiyama T; Hoshino Y; Kurashima A; Sokunaga J; Shibuya S; Shimojima M; Ato M; Mitarai S
Ann Am Thorac Soc; 2017 Jan; 14(1):49-56. PubMed ID: 27788025
[TBL] [Abstract][Full Text] [Related]
9. Nontuberculous mycobacterial pulmonary disease and the potential role of SPR720.
Winthrop KL; Flume P; Hamed KA
Expert Rev Anti Infect Ther; 2023; 21(11):1177-1187. PubMed ID: 37862563
[TBL] [Abstract][Full Text] [Related]
10. Burden of non-tuberculous mycobacterial pulmonary disease in Germany.
Diel R; Jacob J; Lampenius N; Loebinger M; Nienhaus A; Rabe KF; Ringshausen FC
Eur Respir J; 2017 Apr; 49(4):. PubMed ID: 28446559
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of Pulmonary Nontuberculous Mycobacterial Sputum Positivity in Patients with Cystic Fibrosis in the United States, 2010-2014.
Adjemian J; Olivier KN; Prevots DR
Ann Am Thorac Soc; 2018 Jul; 15(7):817-826. PubMed ID: 29897781
[TBL] [Abstract][Full Text] [Related]
12. Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus Complex.
Shin SH; Jhun BW; Kim SY; Choe J; Jeon K; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30104265
[No Abstract] [Full Text] [Related]
13. Pulmonary Mycobacterium avium-intracellulare is the main driver of the rise in non-tuberculous mycobacteria incidence in England, Wales and Northern Ireland, 2007-2012.
Shah NM; Davidson JA; Anderson LF; Lalor MK; Kim J; Thomas HL; Lipman M; Abubakar I
BMC Infect Dis; 2016 May; 16():195. PubMed ID: 27154015
[TBL] [Abstract][Full Text] [Related]
14. [Non-tuberculous mycobacteriosis. What has been coming out].
Kajiki A
Kekkaku; 2011 Feb; 86(2):113-25. PubMed ID: 21404655
[TBL] [Abstract][Full Text] [Related]
15. Distribution of nontuberculous mycobacteria in treated patients with pulmonary disease in Greece - relation to microbiological data.
Manika K; Tsikrika S; Tsaroucha E; Karabela S; Karachaliou I; Bosmi I; Kioumis I; Papavasileiou A
Future Microbiol; 2015; 10(8):1301-6. PubMed ID: 26226382
[TBL] [Abstract][Full Text] [Related]
16. Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort.
Zweijpfenning S; Kops S; Magis-Escurra C; Boeree MJ; van Ingen J; Hoefsloot W
Respir Med; 2017 Oct; 131():220-224. PubMed ID: 28947034
[TBL] [Abstract][Full Text] [Related]
17. Cost of multi drug resistance tuberculosis in Germany.
Diel R; Nienhaus A; Lampenius N; Rüsch-Gerdes S; Richter E
Respir Med; 2014 Nov; 108(11):1677-87. PubMed ID: 25443398
[TBL] [Abstract][Full Text] [Related]
18. Meeting the challenges of NTM-PD from the perspective of the organism and the disease process: innovations in drug development and delivery.
van der Laan R; Snabilié A; Obradovic M
Respir Res; 2022 Dec; 23(1):376. PubMed ID: 36566170
[TBL] [Abstract][Full Text] [Related]
19. Radiological findings in nontuberculous mycobacterial pulmonary diseases: A comparison between the Mycobacterium avium complex and the Mycobacterium abscessus complex.
Nagano H; Kinjo T; Fujita J; Kishaba T
PLoS One; 2022; 17(7):e0271660. PubMed ID: 35862353
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of Nontuberculous Mycobacterial Pulmonary Disease, Germany, 2009-2014.
Ringshausen FC; Wagner D; de Roux A; Diel R; Hohmann D; Hickstein L; Welte T; Rademacher J
Emerg Infect Dis; 2016 Jun; 22(6):1102-5. PubMed ID: 27191473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
